DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Nezulcitinib [inn], Nezulcitinib [usan], Thrx-136377, Cxa4i8ah6a, Td-0903, 2412496-23-0

Molecular Formula

C₃₀H₃₇N₇O₂

Molecular Weight

527.7 g/mol

InChI Key

VQIIUJSNIKEMCK-MHZLTWQESA-N

FDA UNII

CXA4I8AH6A

Nezulcitinib is a lung-selective inhibitor of the Janus associated-kinases (JAKs), with potential immunomodulatory and anti-inflammatory activities. Upon administration via nebulized inhalation, nezulcitinib inhibits the activity of the JAKs, thereby disrupting cytokine-induced activation of JAK-STAT signaling pathways in the airways. This may inhibit the release of pro-inflammatory cytokines and chemokines, reducing inflammatory responses and preventing inflammation-induced damage. The Janus kinase family of non-receptor tyrosine kinases, which includes tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1), tyrosine-protein kinase JAK2 (Janus kinase 2; JAK2), tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) and non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2), plays a key role in cytokine signaling.

1 2D Structure

Nezulcitinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[3-(dimethylamino)azetidin-1-yl]-[(6S)-2-[6-(2-ethyl-4-hydroxyphenyl)-1H-indazol-3-yl]-5-propan-2-yl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone

2.1.2 InChI

InChI=1S/C30H37N7O2/c1-6-18-11-21(38)8-10-22(18)19-7-9-23-24(12-19)33-34-28(23)29-31-25-13-27(37(17(2)3)16-26(25)32-29)30(39)36-14-20(15-36)35(4)5/h7-12,17,20,27,38H,6,13-16H2,1-5H3,(H,31,32)(H,33,34)/t27-/m0/s1

2.1.3 InChI Key

VQIIUJSNIKEMCK-MHZLTWQESA-N

2.1.4 Canonical SMILES

CCC1=C(C=CC(=C1)O)C2=CC3=C(C=C2)C(=NN3)C4=NC5=C(N4)CN(C(C5)C(=O)N6CC(C6)N(C)C)C(C)C

2.1.5 Isomeric SMILES

CCC1=C(C=CC(=C1)O)C2=CC3=C(C=C2)C(=NN3)C4=NC5=C(N4)CN([C@@H](C5)C(=O)N6CC(C6)N(C)C)C(C)C

2.2 Other Identifiers

2.2.1 UNII

CXA4I8AH6A

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (s)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1h-indazol-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3h-imidazo(4,5-c)pyridin-6-yl)methanone

2. Methanone, (3-(dimethylamino)-1-azetidinyl)((6s)-2-(6-(2-ethyl-4-hydroxyphenyl)-1h-indazol-3-yl)-4,5,6,7-tetrahydro-5-(1-methylethyl)-3h-imidazo(4,5-c)pyridin-6-yl)-, Hydrate (1:1)

3. Nezulcitinib Monohydrate

4. Td-0903

5. Td-0903 Monohydrate

6. Thrx-136377

7. Thrx-136377 Monohydrate

2.3.2 Depositor-Supplied Synonyms

1. Nezulcitinib [inn]

2. Nezulcitinib [usan]

3. Thrx-136377

4. Cxa4i8ah6a

5. Td-0903

6. 2412496-23-0

7. (s)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1h-indazol-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3h-imidazo(4,5-c)pyridin-6-yl)methanone

8. [3-(dimethylamino)azetidin-1-yl]-[(6s)-2-[6-(2-ethyl-4-hydroxyphenyl)-1h-indazol-3-yl]-5-propan-2-yl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-6-yl]methanone

9. Unii-cxa4i8ah6a

10. Nezulcitinib [who-dd]

11. Chembl4802163

12. Schembl21772319

13. Gtpl11304

14. Who 11732

15. Example 1 [wo2020051105a1]

16. Hy-132849

17. Cs-0204160

18. (3-(dimethylamino)azetidin-1-yl)((6s)-2-(6-(2-ethyl-4-hydroxyphenyl)-1h-indazol-3-yl)-5-(propan-2-yl)-4,5,6,7-tetrahydro-1h-imidazo(4,5-c)pyridin-6-yl)methanone

19. Methanone, (3-(dimethylamino)-1-azetidinyl)((6s)-2-(6-(2-ethyl-4-hydroxyphenyl)-1h-indazol-3-yl)-4,5,6,7-tetrahydro-5-(1-methylethyl)-3h-imidazo(4,5-c)pyridin-6-yl)-

2.4 Create Date

2020-06-27

3 Chemical and Physical Properties

Molecular Formula	C₃₀H₃₇N₇O₂
Molecular Weight	527.7 g/mol
XLogP3	3.6
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Exact Mass	527.30087345 g/mol
Monoisotopic Mass	527.30087345 g/mol
Topological Polar Surface Area	104 Å²
Heavy Atom Count	39
Formal Charge	0
Complexity	866
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1